Liquid Biopsy Identifies Lung Cancer Biomarkers Faster Than Tissue Tests Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 41(8):33, April 20, 2019. Favorites PDF Get Content & Permissions Free
Higher Doses of Second-Line Nivolumab Safe & Effective for Advanced NSCLC Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 41(8):30, April 20, 2019. Favorites PDF Get Content & Permissions Free
Prophylactic Cranial Irradiation Use Down Sharply for Extensive-Stage SCLC Samson, Kurt Samson, Kurt Less Oncology Times. 41(8):27, April 20, 2019. Favorites PDF Get Content & Permissions Free
Web-Based Guideline Tool Increases NSCLC Patients in Decisions Samson, Kurt Samson, Kurt Less Oncology Times. 41(8):26, April 20, 2019. Favorites PDF Get Content & Permissions Free
Oligometastatic NSCLC: Consolidation Therapy May Provide Survival Edge Samson, Kurt Samson, Kurt Less Oncology Times. 41(8):25,37-37, April 20, 2019. Favorites PDF Get Content & Permissions Free
ZEB1 Throttles Therapeutic Target, Protects KRAS-Mutant Lung Cancer Less Oncology Times. 41(7):32-34, April 5, 2019. Favorites PDF Get Content & Permissions Free
Immunotherapy Advances in Non-Small Cell Lung Cancer Johnson, Melissa; Zimmerman, Lisa J. Johnson, Melissa; Zimmerman, Lisa J. Less Oncology Times. 41(7):12,13,35-35, April 5, 2019. Favorites PDF Get Content & Permissions Free
Lorlatinib (Lorbrena®) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 41(6):5, March 20, 2019. Favorites PDF Get Content & Permissions Free
Complications of Diagnostic Tests Following Lung Cancer Screening Brophy Marcus, Mary Brophy Marcus, Mary Less Oncology Times. 41(6):21-22, March 20, 2019. Favorites PDF Get Content & Permissions Free
Navigating a New Path to Test Peripheral Lung Nodules Holt, Chuck Holt, Chuck Less Oncology Times. 41(6):1-2, March 20, 2019. Favorites PDF Get Content & Permissions Free
Free Lung Cancer Screening Builds Valuable Relationships With Patients Less Oncology Times. 41(4):34, February 20, 2019. Favorites PDF Get Content & Permissions Free
Complication Rates & Costs of Lung Cancer Diagnostic Tests Less Oncology Times. 41(3):28, February 5, 2019. Favorites PDF Get Content & Permissions Free
OAK Trial Shows Fast Progression Is Not More Common With Atezolizumab Less Oncology Times. 41(2):36, January 20, 2019. Favorites PDF Get Content & Permissions Free
Second-Line Nivolumab Is Not Superior to Chemotherapy in SCLC Less Oncology Times. 41(2):21, January 20, 2019. Favorites PDF Get Content & Permissions Free
First-Line Immunotherapy Combination Fails to Improve OS in Lung Cancer Less Oncology Times. 41(2):20, January 20, 2019. Favorites PDF Get Content & Permissions Free
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 40(22):34, November 20, 2018. Favorites PDF Get Content & Permissions Free
Detection of Early-Stage Lung Cancer When Surgical Cure Still Possible Less Oncology Times. 40(21):26, November 5, 2018. Favorites PDF Get Content & Permissions Free
Treatment Resistance in EGFR-Mutant NSCLC & Acquired RET Fusion Less Oncology Times. 40(20):50, October 20, 2018. Favorites PDF Get Content & Permissions Free
Promising Results for Entrectinib Against ROS1-Positive NSCLC Less Oncology Times. 40(20):45, October 20, 2018. Favorites PDF Get Content & Permissions Free
Brigatinib Becomes Potential First-Line Option for ALK-Positive NSCLC Less Oncology Times. 40(20):44, October 20, 2018. Favorites PDF Get Content & Permissions Free
LOXO-292 Durability Update in Patients With RET Fusion-Positive NSCLC Less Oncology Times. 40(20):43, October 20, 2018. Favorites PDF Get Content & Permissions Free
Poziotinib Sustains High Response Rates Against Lung Cancer Mutation Less Oncology Times. 40(19):22, October 5, 2018. Favorites PDF Get Content & Permissions Free
Promising Immunotherapies in Early-Stage Lung Cancer Less Oncology Times. 40(16):16, August 20, 2018. Favorites PDF Get Content & Permissions Free
Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers Less Oncology Times. 40(16):28, August 20, 2018. Favorites PDF Get Content & Permissions Free
Potential Value of Real-World Evidence in Lung Cancer Care Eastman, Peggy Eastman, Peggy Less Oncology Times. 40(16):1,7,13-13, August 20, 2018. Favorites PDF Get Content & Permissions Free
Genome-Wide Sequencing Detects Early Stage Lung Cancer From Blood Samples Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(14):31, July 20, 2018. Favorites PDF Get Content & Permissions Free
Adding Immunotherapy to Chemotherapy in Advanced Squamous Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(14):29, July 20, 2018. Favorites PDF Get Content & Permissions Free
Pembrolizumab Monotherapy Extended Survival in Advanced Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 40(13):36,55-55, July 5, 2018. Favorites PDF Get Content & Permissions Free
Upfront Genetic Testing of Non-Small Cell Lung Cancer Is Cost-Effective Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(13):34, July 5, 2018. Favorites PDF Get Content & Permissions Free
Registry Reveals Low Lung Cancer Screening of Smokers Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(13):33, July 5, 2018. Favorites PDF Get Content & Permissions Free
Lung Cancer: Geriatric Assessment Before Concurrent Chemo-Radiotherapy Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 40(12):39, June 20, 2018. Favorites PDF Get Content & Permissions Free
Handgrip Strength Predicts Survival in Elderly Patients With Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 40(12):34, June 20, 2018. Favorites PDF Get Content & Permissions Free
Neoadjuvant Nivolumab in Patients With Resectable Non-Small Cell Lung Cancer Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(11):41-42, June 5, 2018. Favorites PDF Get Content & Permissions Free
Evaluating Nivolumab + Ipilimumab vs. Standard Chemo in NSCLC Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(11):38,40-40, June 5, 2018. Favorites PDF Get Content & Permissions Free
Treatment for ALK-Positive & ALK-Negative Inflammatory Myofibroblastic Tumors Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(11):35-36, June 5, 2018. Favorites PDF Get Content & Permissions Free
Evaluating Chemotherapy & Pembrolizumab in Metastatic NSCLC Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(11):33-34, June 5, 2018. Favorites PDF Get Content & Permissions Free
Longer Symptom Improvement in ALK-Positive Lung Cancer Less Oncology Times. 40(11):31, June 5, 2018. Favorites PDF Get Content & Permissions Free
Immunotherapy & Long-Term Survival for Lung Cancer Patients Less Oncology Times. 40(11):24, June 5, 2018. Favorites PDF Get Content & Permissions Free
Immunotherapy Shows Promise Among Lung Cancer Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(10):40-41, May 20, 2018. Favorites PDF Get Content & Permissions Free
New Immunotherapy for Lung Cancer Shows Promise of Success Less Oncology Times. 40(9):30, May 5, 2018. Favorites PDF Get Content & Permissions Free
Updated ASTRO Guideline for Palliative Lung Radiation Less Oncology Times. 40(9):27, May 5, 2018. Favorites PDF Get Content & Permissions Free
Crizotinib (Xalkori®) Skirvin, J. Andrew Skirvin, J. Andrew Less Oncology Times. 39(24):30, December 25, 2017. Favorites PDF Get Content & Permissions Free
Osimertinib Improves PFS in Asian EGFR-Mutated Lung Cancer Patients Less Oncology Times. 39(24):51, December 25, 2017. Favorites PDF Get Content & Permissions Free
Mutations in Cerebrospinal Fluid in Lung Cancer With Brain Metastases Less Oncology Times. 39(24):45, December 25, 2017. Favorites PDF Get Content & Permissions Free
Genetic Testing for EGFR Mutations in NSCLC Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(24):20,33-33, December 25, 2017. Favorites PDF Get Content & Permissions Free
Chronic Stress Hormones May Promote Resistance to EGFR Inhibitors Less Oncology Times. 39(23):64, December 10, 2017. Favorites PDF Get Content & Permissions Free
Positive Findings for Nintedanib in Malignant Pleural Mesothelioma Bennett, Christina Bennett, Christina Less Oncology Times. 39(23):27, December 10, 2017. Favorites PDF Get Content & Permissions Free
Maintenance Therapy in Advanced Small Cell Lung Cancer Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(23):1,6,10-10, December 10, 2017. Favorites PDF Get Content & Permissions Free CME
Lung Cancer Driver ALK-Fusion Found in Melanoma Less Oncology Times. 39(22):58, November 25, 2017. Favorites PDF Get Content & Permissions Free
The Use of Liquid Biopsies in Patients With NSCLC Bhadra, Krish; Garwood, Susan; Sharma, Nitika; More Bhadra, Krish; Garwood, Susan; Sharma, Nitika; Walker, Paul Less Oncology Times. 39(22):20-21, November 25, 2017. Favorites PDF Get Content & Permissions Free
Stage III NSCLC Survival Rate Doubles With Standard Radiation Therapy Samson, Kurt Samson, Kurt Less Oncology Times. 39(21):58, November 10, 2017. Favorites PDF Get Content & Permissions Free
Blood Test for Tumor Cell DNA May Help Predict Localized NSCLC Samson, Kurt Samson, Kurt Less Oncology Times. 39(21):57, November 10, 2017. Favorites PDF Get Content & Permissions Free
Nab-Paclitaxel Monotherapy Shows Promise for Previously Treated, Advanced NSCLC Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(21):47, November 10, 2017. Favorites PDF Get Content & Permissions Free
ALUR Study Results Comparing ALK Inhibitor Alectinib vs. Chemotherapy Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(21):46-47, November 10, 2017. Favorites PDF Get Content & Permissions Free
Researchers Describe Rare Phenomenon in Lung Cancer Bennett, Christina Bennett, Christina Less Oncology Times. 39(21):44, November 10, 2017. Favorites PDF Get Content & Permissions Free
Anti-Inflammatory Therapy Cuts Risk of Lung Cancer Less Oncology Times. 39(18):30, September 25, 2017. Favorites PDF Get Content & Permissions Free
First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer Carbone, David P. Carbone, David P. Less Oncology Times. 39(17):28-29, September 10, 2017. Favorites PDF Get Content & Permissions Free
Evaluating First-Line Ceritinib Therapy in ALK-Rearranged NSCLC Patients Simoneux, Richard Simoneux, Richard Less Oncology Times. 39(17):23,24,32-32, September 10, 2017. Favorites PDF Get Content & Permissions Free
Evading Therapeutic Resistance Through Collateral Sensitivity: A Paradigm Shift? Scott, Jacob; Dhawan, Andrew Scott, Jacob; Dhawan, Andrew Less Oncology Times. 39(15):22, August 10th, 2017. Favorites PDF Get Content & Permissions Free
ASTRO Issues Guideline for Use of SBRT in Early-Stage Lung Cancer Less Oncology Times. 39(13):25,28-29, July 10th, 2017. Favorites PDF Get Content & Permissions Free
Brigatinib Granted Accelerated Approval for NSCLC Less Oncology Times. 39(11):39, June 10th, 2017. Favorites PDF Get Content & Permissions Free
Lung Cancer May Go Undiagnosed in Metastatic Kidney Cancer Patients Bowman, I. Alex Bowman, I. Alex Less Oncology Times. 39(11):1,11-11, June 10th, 2017. Favorites PDF Get Content & Permissions Free
Osimertinib Granted Full Approval for NSCLC Less Oncology Times. 39(9):34, May 10th, 2017. Favorites PDF Get Content & Permissions Free
Mutations in Treatment-Resistant NSCLC Can Change Over Time Samson, Kurt Samson, Kurt Less Oncology Times. 39(8):47, April 25th, 2017. Favorites PDF Get Content & Permissions Free
‘Modest’ Toxicity With Checkpoint Inhibitors Plus Radiotherapy for NSCLC Samson, Kurt Samson, Kurt Less Oncology Times. 39(8):45, April 25th, 2017. Favorites PDF Get Content & Permissions Free
NSCLC Treatment Utilization, Survival Rates Hindered By Racial Disparities Samson, Kurt Samson, Kurt Less Oncology Times. 39(8):37, April 25th, 2017. Favorites PDF Get Content & Permissions Free
SBRT Found Safe, Effective in Elderly With Inoperable Early-Stage NSCLC Samson, Kurt Samson, Kurt Less Oncology Times. 39(8):36, April 25th, 2017. Favorites PDF Get Content & Permissions Free
Study Results Support Use of Proton Therapy for Recurrent NSCLC Samson, Kurt Samson, Kurt Less Oncology Times. 39(8):34,51-51, April 25th, 2017. Favorites PDF Get Content & Permissions Free
The Latest Clinical Trials Involving Targeted Therapies for NSCLC Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(7):1,12-14, April 10th, 2017. Favorites PDF Get Content & Permissions Free CME
Chemotherapy Effectiveness & Initiation Time After Lung Cancer Surgery Less Oncology Times. 39(3):30, February 10th, 2017. Favorites PDF Get Content & Permissions Free
First-Line Pembrolizumab Boosts Survival in Advanced Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 39(1):39, January 10th, 2017. Favorites PDF Get Content & Permissions Free
Ceritinib Benefit After Crizotinib for Advanced ALK-Positive Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 39(1):38, January 10th, 2017. Favorites PDF Get Content & Permissions Free
Atezolizumab Immunotherapy Extends Overall Survival in Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 39(1):36, January 10th, 2017. Favorites PDF Get Content & Permissions Free
Pembrolizumab Approved for First-Line Treatment in NSCLC Less Oncology Times. 38(23):29, December 10th, 2016. Favorites PDF Get Content & Permissions Free
FDA Approved PD-L1 (SP142) Assay for Lung Cancer Less Oncology Times. 38(23):27, December 10th, 2016. Favorites PDF Get Content & Permissions Free
Increase in Elderly NSCLC Survival Linked to Stereotactic Body Radiation Samson, Kurt Samson, Kurt Less Oncology Times. 38(23):36, December 10th, 2016. Favorites PDF Get Content & Permissions Free
How to Spread the Word About Lung Cancer Screening Gomez, Jorge E. Gomez, Jorge E. Less Oncology Times. 38(23):30-31, December 10th, 2016. Favorites PDF Get Content & Permissions Free
Lower Dose Afatinib Effective With Fewer Adverse Events in NSCLC Samson, Kurt Samson, Kurt Less Oncology Times. 38(21):30, November 10th, 2016. Favorites PDF Get Content & Permissions Free
Drug-Loaded Synthetic Nanoparticles Can Target Lung Cancer Cells Less Oncology Times. 38(20):30, October 25th, 2016. Favorites PDF Get Content & Permissions Free
A Possible Target to Tackle Drug-Resistant Lung Cancer Cells Less Oncology Times. 38(20):21, October 25th, 2016. Favorites PDF Get Content & Permissions Free
Genotypic Testing of NSCLC Patients Using Cell-Free Circulating Tumor DNA Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 38(20):20-21, October 25th, 2016. Favorites PDF Get Content & Permissions Free
Whole Brain Radiotherapy: No Benefit With Lung Cancer, Brain Metastases Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(19):33, October 10th, 2016. Favorites PDF Get Content & Permissions Free
Whole Brain Radiotherapy: No Benefit With Lung Cancer, Brain Metastases Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(19):33, October 10th, 2016. Favorites PDF Get Content & Permissions Free
Lung Cancer Radiation Therapy Can Increase Heart Disease Mortality Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(16):41-42, August 25th, 2016. Favorites PDF Get Content & Permissions Free
ASCO 2016: Lung Cancer Stinchcombe, Tom Stinchcombe, Tom Less Oncology Times. 38(15):13, August 10th, 2016. Favorites PDF Get Content & Permissions Free
How to Improve Lung Cancer Screening for High-Risk People Eastman, Peggy Eastman, Peggy Less Oncology Times. 38(15):1,8,16-16, August 10th, 2016. Favorites PDF Get Content & Permissions Free
Liquid Biopsy: ‘Method of the Future’ For Lung Cancer Prediction Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(13):40, July 10th, 2016. Favorites PDF Get Content & Permissions Free
Pre-Treated T790M-Positive Lung Cancer: Osimertinib Benefit Confirmed Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(13):39, July 10th, 2016. Favorites PDF Get Content & Permissions Free
Dabrafenib Plus Trametinib Combination Treats Rare Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(13):20, July 10th, 2016. Favorites PDF Get Content & Permissions Free
First-Line Osimertinib Effective in T790m-Mutated EGFR Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(12):35, June 25th, 2016. Favorites PDF Get Content & Permissions Free
Cachexia in NSCLC Patients Reversed With GSHR Agonist Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(8):20-21, April 25th, 2016. Favorites PDF Get Content & Permissions Free
The Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Mansfield, Aaron Mansfield, Aaron Less Oncology Times. 38(7):32-34, April 10th, 2016. Favorites PDF Get Content & Permissions Free
NSCLC: Another Study Finds No Benefit with Erlotinib Beyond Progression DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 38(5):24, March 10th, 2016. Favorites PDF Get Content & Permissions Free
FDA Breakthrough Therapy Status to Third-Generation TKI, BI 1482694, for NSCLC Less Oncology Times. 38(2):29, January 25th, 2016. Favorites PDF Get Content & Permissions Free
How to Best Use Immunotherapy Combinations for Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):30-31, January 25th, 2016. Favorites PDF Get Content & Permissions Free
Best Lung Cancer Research, 2015 Stinchcombe, Tom Stinchcombe, Tom Less Oncology Times. 38(2):1,12-13, January 25th, 2016. Favorites PDF Get Content & Permissions Free
FDA Approves Alecensa (Alectinib) for ALK-Pos NSCLC Less Oncology Times. 38(1):37, January 10th, 2016. Favorites PDF Get Content & Permissions Free
FDA Approves Portrazza for Advanced Squamous NSCLC Less Oncology Times. 38(1):21, January 10th, 2016. Favorites PDF Get Content & Permissions Free
FDA Approval for New Targeted NSCLC Drug Less Oncology Times. 37(24):3, December 25th, 2015. Favorites PDF Get Content & Permissions Free
Lung Cancer: Receipt of Curative Surgery Found to Vary from State to State Less Oncology Times. 37(24):32, December 25th, 2015. Favorites PDF Get Content & Permissions Free
